GenSight Biologics S.A. Logo

GenSight Biologics S.A.

SIGHT | PA

Overview

Corporate Details

ISIN(s):
FR0013183985 (+3 more)
LEI:
549300NK4AB8OUEX1F54
Country:
France
Address:
74 RUE DU FAUBOURG SAINT-ANTOINE, 75012 PARIS
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

GenSight Biologics S.A. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative gene therapies. The company targets retinal neurodegenerative diseases and central nervous system disorders. Its therapeutic approach is built on two core technology platforms: a Mitochondrial Targeting Sequence (MTS) and optogenetics. GenSight's lead product candidate, lenadogene nolparvovec (GS010), is in late-stage clinical development for treating Leber Hereditary Optic Neuropathy (LHON). Its second candidate, GS030, utilizes optogenetics to potentially restore vision in patients with diseases such as retinitis pigmentosa and is advancing through clinical trials.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for GenSight Biologics S.A.. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-22 19:00
Capital/Financing Update
Inside Information / Operations of the issuer (acquisitions, sales...)
English 220.0 KB
2025-07-22 19:00
Share Issue/Capital Change
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
French 207.1 KB
2025-07-11 11:27
Major Shareholding Notification
Franchissement de seuils
French 114.0 KB
2025-07-03 21:19
Share Issue/Capital Change
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
French 247.4 KB
2025-07-03 21:19
Capital/Financing Update
Inside Information / Operations of the issuer (acquisitions, sales...)
English 243.8 KB
2025-06-26 07:30
Regulatory News Service
Inside Information / Other news releases
English 165.8 KB
2025-06-26 07:30
Regulatory News Service
Informations privilégiées / Autres communiqués
French 155.9 KB
2025-06-12 19:02
Regulatory News Service
Inside Information / Other news releases
English 207.0 KB
2025-06-12 19:02
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 176.7 KB
2025-05-13 22:00
Post-Annual General Meeting Information
Inside Information / Other news releases
English 85.1 KB
2025-05-13 22:00
Post-Annual General Meeting Information
Informations privilégiées / Autres communiqués
French 114.2 KB
2025-04-23 20:30
Pre-Annual General Meeting Information
Inside Information / Other news releases
English 82.1 KB
2025-04-23 20:30
Pre-Annual General Meeting Information
Informations privilégiées / Autres communiqués
French 113.3 KB
2025-04-08 15:55
Annual Report (ESEF)
URD 2024
English 22.4 MB
2025-04-08 07:00
Report Publication Announcement
INSIDE INFORMATION / OTHER NEWS RELEASES
English 88.3 KB

Automate Your Workflow. Get a real-time feed of all GenSight Biologics S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for GenSight Biologics S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-05-09 N/A Other Other 5,063,291 1,999,999.95 EUR
2024-02-07 N/A Other Other 5,224,660 1,999,999.85 EUR
2023-11-21 N/A Other Other 3,038,279 2,163,862.30 EUR

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN